Key takeaways
Host: Jeff Morgan, Managing Director, RWE Practice Leader, Deloitte Consulting LLP
Presenters: Jennifer Webster, VP, RWE Platforms & Partnerships, Pfizer
As the acceptance and utilization of real-world evidence (RWE) escalates, it is crucial for biopharmaceutical companies to effectively industrialize their RWE capabilities to generate more value for their organizations. In this discussion, we will explore:
- The prominent macro trends across data, technology, analytics, and Generative AI that are influencing future organizational operations
- Lessons from industry leaders on how they are deriving value from RWE and future projections they foresee
Meet the host
Jeff Morgan
Jeff Morgan is a managing director at Deloitte Consulting LLP and leads ConvergeHEALTH by Deloitte’s Real World Evidence (RWE) practice. He has over 22 years of relevant life sciences experience spanning pharmaceuticals and medical technology manufacturers. He has significant experience helping life sciences companies leverage digital health data to transform how drugs are developed, commercialized, and reimbursed. Morgan’s work includes strategy development, system design, and data analytics platform implementations and operations. He has led several large-scale digital transformations to create new capabilities to leverage RWD and other digital health data to unlock high-value use cases across the product life cycle.
Resources
